Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Standard BioTools Inc shares valued at $1,344 were sold by Kim Hanjoon Alex on May 23 ’25. At $0.94 per share, Kim Hanjoon Alex sold 1,428 shares. The insider’s holdings dropped to 930,286 shares worth approximately $1.0 million following the completion of this transaction.
Also, Mackay Sean sold 13,217 shares, netting a total of over 12,437 in proceeds. Following the sale of shares at $0.94 each, the insider now holds 843,076 shares.
Before that, Egholm Michael had sold 5,473 shares from its account. In a trade valued at $5,150, the President & CEO traded Standard BioTools Inc shares for $0.94 each. Upon closing the transaction, the insider’s holdings decreased to 5,473 shares, worth approximately $2.96 million.
As published in a research note from KeyBanc Capital Markets on February 27, 2025, Standard BioTools Inc [LAB] has been rated down from an Overweight to a Sector weight. Analysts at TD Cowen started covering the stock with ‘”a Buy”‘ outlook in a report released in mid April. As of April 04, 2024, Jefferies has initiated its “Buy” rating for LAB. Earlier on July 12, 2023, KeyBanc Capital Markets initiated its rating. Their recommendation was “an Overweight” for LAB stock.
Analyzing LAB Stock Performance
During the last five days, there has been a drop of approximately -0.92%. Over the course of the year, Standard BioTools Inc shares have dropped approximately -38.29%. Shares of the company reached a 52-week high of $2.1400 on 01/15/25 and a 52-week low of $0.9200 on 05/23/25.
Support And Resistance Levels for Standard BioTools Inc (LAB)
According to the 24-hour chart, there is a support level at 1.0533, which, if violated, would cause prices to drop to 1.0267. In the upper region, resistance lies at 1.1033. The next price resistance is at 1.1267. RSI (Relative Strength Index) is 50.49 on the 14-day chart, showing neutral technical sentiment.
